Gut Microbiome Test Results: What They Cannot Measure

A gut microbiome test can be accurate and still answer the wrong question. The organisms highlighted on a report live quietly in people who feel well, and none of it describes what your own body is doing.

A gut microbiome test can be entirely accurate and still answer a question that cannot help you. The printout is persuasive: a logo, two lines under yellow highlighter, a protocol waiting at the end. What the panel did was take attendance in one sample. It named who was present. It said nothing about what any of them were doing, and nothing whatever about what your own body is doing while they live there. The video The Wrong Enemy on Your Stool Report carries that argument from The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes. What follows is the measuring half of it.

What does a gut microbiome test actually measure?

The gut is the first brain, and it rearranges its population from one meal to the next. Vagal traffic moves it, and so does whatever arrives in the nutrient stream, which means a species list is a photograph taken on one morning. Work leaves a different kind of evidence: the metabolites a community makes, the immune response it provokes, the gases that come off fermentation. An international consensus panel with sixty-nine authors on it went through the versions of these panels sold straight to the public and could not find evidence that they help a patient in practice. Sixty-nine specialists rarely converge on anything. They converged on that.

The two lines most people carry anyway

Start with the yeast, since it sells the most protocols. Among 317 stool samples from a healthy Human Microbiome Project cohort, Candida albicans appeared in 80.8 percent and baker’s yeast in 96.8 percent. A positive yeast line describes the species, not the person holding the report. Much of the fungal signal traces back to the mouth and the plate, and brushing your teeth more often lowers it.

I should be honest about my own part in this. For years I read a highlighted fungal line as a finding and wrote the antifungal, because that is what I had been taught the line meant. What changed my practice was a randomized, double-blind test of nystatin in the exact symptom cluster patients still bring me: whole-body symptom scores improved 25 percent on the active regimens and 23 percent on placebo alone. The drug cleared the problem it is genuinely indicated for and nothing else. That is what a real indication looks like from the inside.

The protozoan is stranger. Of 296 healthy Malian children tested by PCR, 147 carried Blastocystis, and those children had richer and more diverse bacterial communities than the children without it. An Italian series holds the honest limit: researchers there found it in 22.3 percent of people whose immune systems were weakened and 6.8 percent of people whose were not. Immune status is the variable that decides whether the organism matters, and that judgment belongs to your physician, not to a highlighter.

Stool and microbiome panels are not Measura tests

This needs saying plainly. Measura [Cardiometabolic and Autonomic Health Analysis] does not run stool panels, microbiome sequencing or breath tests. Those are different tests, ordered somewhere else. Measura measures the host — the metabolic, vascular, autonomic and body-composition picture of the person carrying the flora. It measures; it does not diagnose disease on its own and it does not treat. Results go to your own physician to read alongside your history.

What can be measured in you

Laboratory panels put numbers on the metabolic and inflammatory terrain — metaflammation, the low-grade inflammation that keeps a whole system irritable.
Bioimpedance body composition separates muscle from fat, which a bathroom scale cannot do at any price.
Indirect calorimetry measures resting metabolic rate rather than estimating it from an equation built on somebody else’s body.
Heart rate variability and autonomic nervous system testing describe how the involuntary nervous system is regulating you, which is the same vagal wiring the first brain answers to.
Sudomotor testing checks how the sweat glands of your hands and feet respond, a window on the small nerve fibers there, which matters when burning or numb feet showed up alongside the gut symptoms.

Why bother, when the organisms themselves are not the target? Because the terrain is measurable and the census is not the disease. Bacteria that make butyrate drive the colon’s lining cells to consume oxygen, which keeps that surface airless; thin those producers out and oxygen leaks in, and the families that expand are precisely the ones equipped to breathe it. That chain was mapped in mice, so hold it as mechanism rather than proof. The human end of it comes from 7,211 Finnish adults followed as long as 15 years, where a diversity score was not significantly associated with dying, while the load of Enterobacteriaceae came with a hazard ratio of 1.14, and the top quarter of that load ran a 34 percent greater risk of death than the bottom quarter. Composition mattered. The headline number on a consumer report did not.

Then the driver nobody prints beside the result. A test that finds something in most healthy people will sell a protocol to most of the people who buy one. The laboratory sells the detection, an online clinic sells the eviction, and your flora settles the difference. Nobody needs to be a villain for an incentive to work that way. And the eviction is measurable too: in 66 healthy adults given a single ordinary antibiotic, fecal diversity stayed reduced for as long as 4 months after clindamycin and 12 months after ciprofloxacin, with the butyrate producers taking the worst of it.

What to take to your appointment

Every antibiotic and antimicrobial course you can reconstruct, counted as courses rather than years, and what each one was given for.
Your usual stool consistency across two weeks. It moves a diversity score more than most reports admit.
Your whole medication list. Acid-suppressing drugs, diabetes drugs and antipsychotics all weaken the resident community’s grip on newcomers, and none of them arrives labeled as a gut drug.
A question about the plan: if this organism is treated and cleared, which symptom should change, and by when?
A question about measurement: can my metabolic, autonomic and body-composition numbers be measured instead of described?

None of this is a reason to start, stop or change a prescription on your own. Take the report and the questions to the physician who knows your history. Unmeasured is unmanaged, and the alternative to measuring is another highlighted line, another eviction, and a thinner room to live in each time.

Every study named above, with its full numbers and the things it cannot show, sits in the companion deep dive for The Angry Gut. For the plain version of what this service does and does not do, read what Measura actually measures, and the metabolic backdrop is in insulin resistance and metabolic health. The meal-timing side of the same story is visceral and subcutaneous fat and the endpoint that counts, and the version written for clinicians is when a stool finding should change care.

Frequently asked questions

Are gut microbiome tests worth it?

A test is useful for curiosity and weak for decisions. The organisms it names are carried by large numbers of people who feel perfectly well, and a fungal result resembles the same person over time no better than it resembles a stranger. A consensus panel of sixty-nine specialists found no proven value for the consumer versions. Read a detection as a question to ask, never as an instruction to follow. See what a test result can and cannot tell you.

If my report says candida, do I need an antifungal?

Rarely. Most often it means you have a mouth and you eat. Four out of five people in a healthy cohort carried the yeast, and stool fungal levels drop when people brush their teeth more often. Genuine fungal expansion happens in immunosuppressed patients after bacterial loss, and it bears no resemblance to a consumer printout. Take the result to your physician, not to a protocol. Bring questions worth asking your doctor to that visit.

Should Blastocystis hominis be treated?

That depends on your immune status and your symptoms, which is why it is a physician’s decision rather than a panel’s. In healthy children, carriage came with a richer community than in children who tested clean. In the Italian series it was three times more common in immunocompromised patients, and there it can matter. Treating a marker of a good gut is a different matter. The physician version is when a Blastocystis finding changes care.

What can Measura measure if it does not test my stool?

The host, not the flora. Laboratory panels, body composition, resting metabolic rate, autonomic regulation, heart rate variability and small-fiber sweat function are all measurable in a single visit, and each describes how your body is running rather than who is living in your colon. Your physician then reads those numbers against your symptoms. Read how results are explained.

Who should have this kind of testing?

People whose symptoms have outlasted their explanations: years of bloating and fatigue with normal structural tests, a long medication list, repeated antimicrobial courses, unexplained weight or muscle change, or numb and burning feet alongside gut trouble. The point is not another organism. The point is finding the measurable parts of the problem that nobody has put a number on. See who should be tested.

How should I prepare for a gut microbiome test?

Know what moves the result before you trust it. Track your usual stool consistency across two weeks, because it shifts a diversity score more than most reports admit. List every antibiotic course: after a single ordinary antibiotic, fecal diversity stayed reduced for as long as 4 months after clindamycin and 12 months after ciprofloxacin. Bring your full medication list to the physician who reads the report.

Measure the terrain, not the census

Ask about cardiometabolic, autonomic and body-composition testing so your physician can see how your body is running instead of which organisms showed up in one sample.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Nash, A. K., Auchtung, T. A., Wong, M. C., Smith, D. P., Gesell, J. R., Ross, M. C., Stewart, C. J., Metcalf, G. A., Muzny, D. M., Gibbs, R. A., Ajami, N. J., & Petrosino, J. F. (2017). The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome, 5(1), 153. https://doi.org/10.1186/s40168-017-0373-4
Auchtung, T. A., Fofanova, T. Y., Stewart, C. J., Nash, A. K., Wong, M. C., Gesell, J. R., Auchtung, J. M., Ajami, N. J., & Petrosino, J. F. (2018). Investigating colonization of the healthy adult gastrointestinal tract by fungi. mSphere, 3(2), e00092-18. https://doi.org/10.1128/mSphere.00092-18
Dismukes, W. E., Wade, J. S., Lee, J. Y., Dockery, B. K., & Hain, J. D. (1990). A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome. The New England Journal of Medicine, 323(25), 1717-1723. https://doi.org/10.1056/NEJM199012203232501
Kodio, A., Coulibaly, D., Koné, A. K., Konaté, S., Doumbo, S., Guindo, A., Bittar, F., Gouriet, F., Raoult, D., Thera, M. A., & Ranque, S. (2019). Blastocystis colonization is associated with increased diversity and altered gut bacterial communities in healthy Malian children. Microorganisms, 7(12), 649. https://doi.org/10.3390/microorganisms7120649
Gabrielli, S., Furzi, F., Fontanelli Sulekova, L., Taliani, G., & Mattiucci, S. (2020). Occurrence of Blastocystis subtypes in patients from Italy revealed association of ST3 with a healthy gut microbiota. Parasite Epidemiology and Control, 9, e00134. https://doi.org/10.1016/j.parepi.2020.e00134
Salosensaari, A., Laitinen, V., Havulinna, A. S., Meric, G., Cheng, S., Perola, M., Valsta, L., Alfthan, G., Inouye, M., Watrous, J. D., Long, T., Salido, R. A., Sanders, K., Brennan, C., Humphrey, G. C., Sanders, J. G., Jain, M., Jousilahti, P., Salomaa, V., … Niiranen, T. (2021). Taxonomic signatures of cause-specific mortality risk in human gut microbiome. Nature Communications, 12(1), 2671. https://doi.org/10.1038/s41467-021-22962-y
Zaura, E., Brandt, B. W., Teixeira de Mattos, M. J., Buijs, M. J., Caspers, M. P. M., Rashid, M.-U., Weintraub, A., Nord, C. E., Savell, A., Hu, Y., Coates, A. R., Hubank, M., Spratt, D. A., Wilson, M., Keijser, B. J. F., & Crielaard, W. (2015). Same exposure but two radically different responses to antibiotics: Resilience of the salivary microbiome versus long-term microbial shifts in feces. mBio, 6(6), e01693-15. https://doi.org/10.1128/mBio.01693-15
Porcari, S., Mullish, B. H., Asnicar, F., Ng, S. C., Zhao, L., Hansen, R., O’Toole, P. W., Raes, J., Hold, G., Putignani, L., Hvas, C. L., Zeller, G., Koren, O., Tun, H., Valles-Colomer, M., Collado, M. C., Fischer, M., Allegretti, J., Iqbal, T., … Ianiro, G. (2025). International consensus statement on microbiome testing in clinical practice. The Lancet Gastroenterology & Hepatology, 10(2), 154-167. https://doi.org/10.1016/S2468-1253(24)00311-X